Parabilis Medicines, Inc.
PBLS
$28.80
$2.449.26%
NASDAQ
| 03/31/2026 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 9.70M | 5.28M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 47.45M | 39.18M | |||
| Operating Income | -47.45M | -39.18M | |||
| Income Before Tax | -45.32M | -38.33M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -45.32M | -38.33M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -45.32M | -38.33M | |||
| EBIT | -47.45M | -39.18M | |||
| EBITDA | -46.85M | -38.53M | |||
| EPS Basic | -22.47 | -15.49 | |||
| Normalized Basic EPS | -8.98 | -7.71 | |||
| EPS Diluted | -22.47 | -15.49 | |||
| Normalized Diluted EPS | -8.98 | -7.71 | |||
| Average Basic Shares Outstanding | 3.15M | 3.10M | |||
| Average Diluted Shares Outstanding | 3.15M | 3.10M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||